Reply to 'Low-grade intraductal carcinoma of the prostate: an idea whose time has not yet come': evidence-based medicine suggests that the time is now

In the above-referenced commentary,1 Murali Varma raises two valid concerns regarding implications for communication from the message of our study2. First, introducing a term ”Atypical Intraductal Proliferation (AIP)” or “low-grade intraductal carcinoma (IDC-P)” for which there are no well-defined morphological cut-offs or criteria and, second, for the risk of overtreatment. In this author's experience which is based on current2 and previous studies,3-6 AIPs represent significant lesions and must be distinguished from HGPIN. Morphologically, the vast majority of AIPs present with cribriform morphology which have been increasingly recognized as significant lesions. This article is protected by copyright. All rights reserved.